Longeveron Inc. (LGVN)
1.46
-0.10 (-6.41%)
At close: Apr 03, 2025, 1:50 PM
-6.41% (1D)
| Bid | 1.13 |
| Market Cap | 21.84M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.62 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -1.05 |
| Analyst | Buy |
| Ask | 1.85 |
| Volume | 62,750 |
| Avg. Volume (20D) | 293,370 |
| Open | 1.53 |
| Previous Close | 1.56 |
| Day's Range | 1.44 - 1.59 |
| 52-Week Range | 0.77 - 6.40 |
| Beta | 0.36 |
About LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, a...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2021
Employees 25
Stock Exchange NASDAQ
Ticker Symbol LGVN
Website https://www.longeveron.com
Analyst Forecast
According to 3 analyst ratings, the average rating for LGVN stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 584.93% from the latest price.
Stock Forecasts1 month ago
-0.65%
Longeveron shares are trading higher after the com...
Unlock content with
Pro Subscription
8 months ago
+0.87%
Longeveron shares are trading higher after the company announced study results from the CLEAR MIND Phase 2a clinical trial of Lomecel-B in mild Alzheimer's disease, meeting its key objectives to advance data supporting a favorable benefit/risk profile.
